ANGLE plc称Peter Collins为临时首席执行官,Klaas de Boer高级顾问,称其为CelLBxHealth plc。 ANGLE plc named Peter Collins interim CEO and Klaas de Boer senior advisor as it rebrands to CelLBxHealth plc.

ANGLE plc于2025年10月16日宣布, Peter Collins已被任命为临时CEO, Klaas de Boer是董事会的高级顾问。 ANGLE plc announced on October 16, 2025, that Peter Collins has been named interim CEO and Klaas de Boer as senior advisor to the board. 柯林斯在肿瘤诊断和药物研制方面工作超过25年,由警卫保健、GSK和Inivata等部门担任,将在过渡时期起带头作用。 Collins, with over 25 years in oncology diagnostics and drug development from roles at Guardant Health, GSK, and Inivata, will lead during a transition period. 来自麦肯锡和风险资本的财务和技术专家De Boer将在第四季度的重组和筹资阶段提供协助。 De Boer, a finance and technology expert from McKinsey and venture capital, will assist during a restructuring and funding phase in the fourth quarter. 该公司将改名为CelLBxHealth plc, 经营一个有专利的CTC平台,用于癌症研究和临床使用。 The company, set to rebrand as CelLBxHealth plc, operates a patented CTC platform for cancer research and clinical use. 该公告包括欧盟《市场滥用条例》规定的内部信息。 The announcement includes inside information under EU Market Abuse Regulation.